Filing Details
- Accession Number:
- 0001127602-21-002274
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2021-01-21 17:17:00
- Reporting Period:
- 2021-01-19
- Accepted Time:
- 2021-01-21 17:17:00
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
64803 | Cvs Health Corp | CVS | Retail-Drug Stores And Proprietary Stores (5912) | 050494040 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1194413 | J Larry Merlo | One Cvs Drive Woonsocket RI 02895- | President And Ceo | Yes | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2021-01-19 | 64,350 | $74.29 | 586,222 | No | 4 | M | Direct | |
Common Stock | Disposition | 2021-01-19 | 62,893 | $77.00 | 523,329 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | M | Direct | |
No | 4 | S | Direct |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common Stock | Stock Option | Disposition | 2021-01-19 | 64,350 | $0.00 | 64,350 | $74.29 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
271,347 | 2015-04-01 | 2021-04-01 | No | 4 | M | Direct |
Reported Non-Derivative Holdings
Sec. Name | Remaning Holdings | Nature of Ownership | Explanation |
---|---|---|---|
Common Stock | 403,808 | Indirect | By Trust As Beneficiary |
Common Stock (Restricted) | 40,701 | Direct | |
Esop Common Stock | 7,304 | Indirect | By ESOP |
Stock Unit | 684,489 | Direct |
Reported Derivative Holdings
Sec. Name | Sec. Type | Price | Date | Expiration Date | Amount | Remaning Holdings | Nature of Ownership |
---|---|---|---|---|---|---|---|
Common Stock | Phantom Stock Credits | $1.00 | 5,152 | 5,152 | Direct | ||
Common Stock | Stock Option | $102.26 | 2016-04-01 | 2022-04-01 | 273,929 | 273,929 | Direct |
Common Stock | Stock Option | $104.82 | 2017-04-01 | 2023-04-01 | 286,787 | 286,787 | Direct |
Common Stock | Stock Option | $78.05 | 2018-04-03 | 2024-04-03 | 338,105 | 338,105 | Direct |
Common Stock | Stock Option | $62.21 | 2019-04-01 | 2025-04-01 | 394,091 | 394,091 | Direct |
Common Stock | Stock Option | $54.19 | 2020-04-01 | 2029-04-01 | 545,419 | 545,419 | Direct |
Common Stock | Stock Option | $58.34 | 2021-04-01 | 2030-04-01 | 478,711 | 478,711 | Direct |
Expiration Date | Amount | Remaning Holdings | Nature of Ownership |
---|---|---|---|
5,152 | 5,152 | Direct | |
2022-04-01 | 273,929 | 273,929 | Direct |
2023-04-01 | 286,787 | 286,787 | Direct |
2024-04-03 | 338,105 | 338,105 | Direct |
2025-04-01 | 394,091 | 394,091 | Direct |
2029-04-01 | 545,419 | 545,419 | Direct |
2030-04-01 | 478,711 | 478,711 | Direct |
Footnotes
- All sales were effected pursuant to a Rule 10b5-1 plan. The transaction was a sell-to-cover exercise, with shares sold to cover the option exercise price and taxes, and the reporting person retaining all remaining shares.
- Option became exercisable in four equal annual installments, commencing 4/1/2015.
- Each share credit is equivalent to one share; 1-for-1 conversion.
- Reflects year end company match share credits under a non-qualified deferred compensation plan; share credits are payable in cash only, at such time as has been elected by the reporting person.
- Reflects year end company match share credits under a non-qualified deferred compensation plan; share credits are payable in cash only, at such time as has been elected by the reporting person.
- Option became exercisable in four equal annual installments, commencing 4/1/2016.
- Option became exercisable in four equal annual installments, commencing 4/1/2017.
- Option became exercisable in four equal annual installments, commencing 4/3/2018.
- Option became exercisable in four equal annual installments, commencing 4/1/2019.
- Option became exercisable in four equal annual installments, commencing 4/1/2020.
- The number of shares subject to the option were calculated using a 30-day average price.
- Option becomes exercisable in four equal annual installments, commencing 4/1/2021.